Abstract
The rationale for the HOT study is mainly based on the findings of the Italian Tamoxifen Prevention Study, where 5,408 healthy hysterectomized women aged 35–70 years were randomized to 20 mg/day of tamoxifen or placebo for 5 years. After 81.2 months median follow-up, 79 breast cancers occurred (34 on tamoxifen versus 45 on placebo, p=0.215). In the subgroup of 1,580women who used estrogen replacement therapy (ERT) at some point during the study, 23 breast cancers were observed: 17 on placebo and 6 on tamoxifen (hazard ratio=0.35, 95% CI, 0.14–0.89). Pharmacokinetic and pharmacodynamic (surrogate endpoint biomarkers) studies showed that a lower dose of tamoxifen (such as 5 mg/day) does not affect the drug’s activity on several biomarkers of both cardiovascular and breast cancer risk. We therefore propose a multicenter placebo-controlled phase III trial in postmenopausal healthy women on hormone replacement therapy (HRT) to assess whether the combination of HRTand low-dose tamoxifen retains the benefits while reducing the risks of either.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Pritchard KI (1998) Is tamoxifen effective in prevention of breast cancer? Lancet 352:80–81
Veronesi U, Maisonneuve P, Costa A, et al (1999) Drop-outs in tamoxifen prevention trials. Lancet 353:244
Fisher B, Costantino JP, Wickerham DL, et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388
Chang J, Powles TJ, Ashley SE, et al (1996) The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann OncoI 7:671–675
Decensi A, Robertson C, Rotmensz N, et al (1998) Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer 78:572–578
Collaborative Group On Hormonal Factors In Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059
Gapstur SM, Morrow M, Sellers A (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281:2091–2097
Schairer C, Lubin J, Troisi R, et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491
Schairer C, Gail M, Byrne C, et al (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91:264–270
Colditz GA, et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–1593
Colditz GA, Rosner B (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 147:64S
Persson I, Weiderpass E, Bergkvist L, et al (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10:253–260
Ross RK, Paganini-Hill A, Wan PC, et al (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332
Magnusson C, Perssonh I, Adami O (2000) More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:1183–1184
Willett W, Colditz CG, Stampfer M (2000) Postmenopausal estrogens-opposed, unopposed, or none of the above. JAMA 283:534–535
Slowinska-Srzednicka J. Zgliczynski S, Jeske W, et al (1992) Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest 15:533–538
Weissberger AJ, Hol KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72:374–381
Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al (1991) Different hepatobiliary effects of oral and trans dermal estradiol in postmenopausal women. Gastroen terol. 100:482–488
Walsh BW, Li H, Sacks FM (1994) Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35:2083–2093
Chetkowski RJ, Meldrum DR, Steingold KA, et al (l986) Biologic effects of trans dermal estradiol. N Engl J Med 314:1615–1620
Khan SA, Rogers MA, Khurana KK, et al (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37–42
Rutqvist E, Johansson H, Signomklao T, et al (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645–651
Jordan VC (1999) Tamoxifen: too much for a good thing? J Clin OncoI 17:2629–2630
Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al (l998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461–1467
Decensi A, Gandini S, Guerrieri-Gonzaga A, et al (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. J Clin Oncol 17:2633–2638
Guerrieri-Gonzaga A, et al (2000) Correlation between tamoxifen wash-out and biomarkers recovery in a primary preventiontrial (abstract). Proc Am Assoc Cancer Res 41:1419
Fabian C, Sternson L, El-Serafi M, et al (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48:876–882
Langan-Fahey SM, Tormey DC, Jordan VC (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26:883–888
Lien EA, Solheim E, Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837–4844
Robinson SP, Langan-Fahey SM, Johnson DA, et al (1991) Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36–43
Sutherland RL, et al (l987) Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 27:891–897
Lippman M, Bolan G, Huff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595–4601
Wakeling AE (1989) Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 34:183–188
Maltoni C, et al (1996) Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W (eds) The scientific bases of cancer chemoprevention. pp 197–217
Breuer B, Wallenstein S, Anderson R (1998) Effect of tamoxifen on bon e fractures in older nursing home residents. J Am Geriatr Soc 46:968–972
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Decensi, A., Galli, A., Veronesi, U. (2003). HRT Opposed to Low-Dose Tamoxifen (HOT Study): Rationale and Design. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics. Recent Results in Cancer Research, vol 163. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55647-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-55647-0_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62892-4
Online ISBN: 978-3-642-55647-0
eBook Packages: Springer Book Archive